An interventional study of Brain stimulation in Major Depressive Disorder, sponsored by Icahn School of Medicine at Mount Sinai. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Icahn School of Medicine at Mount Sinai · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Depressive Disorder, Major by Icahn School of Medicine at Mount Sinai — 4 open to participants now, 5 under way, none of them phase 3. Depressive Disorder, Major · Icahn School of Medicine at Mount Sinai.
Among the 19 studies in Depressive Disorder, Major by Icahn School of Medicine at Mount Sinai, this one is the 13th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2021, is one of 8 with no phase, and was the 13th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →4 of the 19 studies in Depressive Disorder, Major by Icahn School of Medicine at Mount Sinai are open now, in 1 country. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18–65 · Healthy volunteers
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18–70 · Healthy volunteers
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 21–80
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18–90
By country, each count listing its studies:
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 4 1
First in 2006; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 34 across the 18 interventional studies, 135 across the 1 observational. Of the 13 that completed or were terminated, 6 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
Icahn School of Medicine at Mount Sinai is the lead sponsor of 776 studies on the registry; 175 are open to participants now.
Of its 125 completed or terminated interventional studies of FDA-regulated products, 83 (66%) have results posted.
1 of the studies in Depressive Disorder, Major by Icahn School of Medicine at Mount Sinai that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559826Icahn School of Medicine at Mount SinaiKetamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Depressive Disorder, Major by Icahn School of Medicine at Mount Sinai, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Novel invasive neurostimulation stimulation strategies through neurosurgical interventions are emerging as a promising therapeutical strategy for major depressive disorder. These have been applied mostly to the anterior cingulate cortex, but other limbic brain regions have shown promise as anatomical targets for new neurostimulation strategies. The researchers seek to study neural activity in limbic brain areas implicated in decision behavior and mood regulation to identify novel targets for treatment through electrical stimulation. To do this, the study team will record local field potentials (LFPs) from the orbitofrontal cortex, hippocampus and amygdala of epilepsy participants undergoing invasive monitoring (intracranial encephalography, iEEG) during choice behavior. Leveraging the high co-morbidity of depression and intractable epilepsy (33-50%), neural responses will be compared to reward across depression status to identify abnormal responses in depression. Finally, the researchers will use these as biomarkers to guide development of neurostimulation strategies for the treatment of depression.
Participants (n=24) will complete a decision-making task in which participants will make decisions under uncertainty and seek to maximize rewards. The researchers will assess behavioral (risk attitudes) and neural (LFP) responses using a combination of intracranial recordings and computational modeling. A subset of patients will complete the game a second time under electrical stimulation of pre-identified anatomical targets in orbitofrontal cortex, hippocampus or amygdala. In addition, patients' depression status will be assessed through questionnaires (BDI-II and HDSA). Finally, the researchers will examine whether electrical stimulation results in behavioral or mood modulation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- The study will follow clinical criteria for epilepsy patient recruitment for invasive monitoring. As a results, individuals of adults of all ages are expected to be included in this study.
Exclusion Criteria:
Participants with depression to undergo brain stimulation
Procedure: Brain stimulation
Brain stimulation will be performed after collection of clinical seizure data. Bipolar stimulation to one or several adjacent electrodes will be applied. Stimulation design will be either determined prior to testing or designed according to results from neurobehavioral assessments. Stimulation will consist of biphasic, constant-current trains of stimulation pulses at 100 Hz, with 100 ms pulse width or a sinusoidal wave of a predefined mean band frequency (i.e. 6Hz for θ, 11Hz for α, 20Hz for β, etc.). Stimulation intensity will be ≤6 mA, consistent with parameters used for clinical mapping, for the duration of the behavioral task or for short (2-3 s) periods of time at given epochs during the task (i.e. outcome evaluation). Clinical personnel will be available during stimulation to help monitor stimulation-induced after-discharges; if any are detected, stimulation intensity will be dialed down or terminated.
Gambling Task
Risk attitudes will be evaluated behaviorally. Patients' behavior will in examined in experimental task (a gambling task) to determine overall proportion of risky choices (gambles) and indifference points (expected gamble value at which the patient is equally likely to choose a gamble or a safe bet). Score from 0%-100%, with higher percent indicating choosing the risky gamble more often.
Time frame: Day 1
Beck's Depression I-II (BDI-II) score
Self-reported mood questionnaire. BDI-II total scale 0-63, with higher score indicating more severe depression.
Time frame: Day 1
Hamilton scales for depression and anxiety (HSDA)
HSDA comprise the Hamilton Depression Rating Scale (HDRS) and the Hamilton Anxiety Rating Scale (HAM-A). These are clinician-administered mood and anxiety reports. HDRS total score range from 0-81 with higher scores indicating greater depression severity. HAM-A total score range from 0-56, with higher score indicating higher severity. HRDS full scale from 0-137 where scores of 0-7 indicate normal range, whereas a score of 20 or higher indicates at least moderate severity.
Time frame: Day 1
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
Supporting information: Study protocol
Time frame: Beginning 3 months and ending 5 years following article publication.
Access criteria: Researchers who provide a methodologically sound proposal. Any purpose. Proposals should be directed to ignacio.saez@mssm.edu. To gain access, data requestors will need to sign a data access agreement. Data are available for 5 years at a third party website (Link to be included in the URL field below).
Ran from Oct 2021 to primary completion in May 2026, 55 months.
Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's 55 months is above that.
Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Aug 2027 → May 2026 and completion Aug 2027 → May 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Icahn School of Medicine at Mount Sinai →